RETAIN: Risk-Enabled Therapy After Neoadjuvant Chemo for MIBC
By Daniel M. Geynisman, MD - Last Updated: February 23, 2023Daniel M. Geynisman, MD, Chief of the Division of Genitourinary Medical Oncology, Fox Chase Cancer Center, explains the results and utility of the RETAIN trial for bladder sparing in patients with MIBC.
Post Tags:ASCO GU 2023-Bladder Cancer
Related Posts
Phouc Tran, MD, PhD, highlights the challenges of accurate risk stratification for newly diagnosed localized prostate cancer.
Petros Grivas, MD, PhD, highlights the practice-changing studies that have come out of the ASCO GU 2023 Symposium.
Michael Atkins, MD, discusses TFS outcomes from the phase II study and argues for immunotherapy in favorable-risk patients.
Steven Campbell, MD, PhD, overviews the surgical options available for patients with localized renal cell carcinoma.
Andrea Necchi, MD, speculates on the applicability of pembrolizumab monotherapy for BCG-unresponsive NMIBC.
670 Madison Ave.
Manalapan, NJ 07726